ArticleBlood2018

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

Eugenio Morelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.